Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Malignant Melanoma

  Free Subscription

Articles published in J Invest Dermatol

Retrieve available abstracts of 138 articles:
HTML format

Single Articles

    September 2020
  1. OLSEN CM, Pandeya N, Dusingize JC, Thompson BS, et al
    Can people correctly assess their future risk of melanoma?
    J Invest Dermatol. 2020 Sep 11. pii: S0022-202X(20)31964.

  2. ZHANG C, Smalley I, Emmons MF, Sharma R, et al
    Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma.
    J Invest Dermatol. 2020 Sep 2. pii: S0022-202X(20)32047.
    PubMed     Abstract available

    The Melanoma JID Connector Collection: An Introduction.
    J Invest Dermatol. 2020;140:1690.

  4. LEE B, Sahoo A, Sawada J, Marchica J, et al
    MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAF(V600E)-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance.
    J Invest Dermatol. 2020 Sep 1. pii: S0022-202X(20)32043.
    PubMed     Abstract available

    August 2020
  5. SWAMINATHAN K, Campbell A, Papalazarou V, Jaber-Hijazi F, et al
    The RAC1 target NCKAP1 plays a crucial role in progression of BRAF/PTEN -driven melanoma in mice.
    J Invest Dermatol. 2020 Aug 7. pii: S0022-202X(20)31956.
    PubMed     Abstract available

    July 2020
  6. LE K, Matar H, Gupta M
    Bromodomain epigenetic protein promotes metastatic potential in melanoma cells via increased invasiveness and decreased macrophage-mediated phagocytosis.
    J Invest Dermatol. 2020 Jul 6. pii: S0022-202X(20)31733.

    June 2020
  7. WANG P, Li Y, Ma Y, Zhang X, et al
    Comprehensive investigation into the role of ubiquitin conjugating enzyme E2S (UBE2S) in melanoma development.
    J Invest Dermatol. 2020 Jun 27. pii: S0022-202X(20)31729.
    PubMed     Abstract available

    May 2020
  8. TRUCCO LD, Mundra PA, Garcia-Martinez P, Hogan K, et al
    Map3k1 Loss Cooperates With Braf(V600E) to Drive Melanomagenesis.
    J Invest Dermatol. 2020 May 22. pii: S0022-202X(20)31598.

  9. NGUYEN MQ, Teh JLF, Purwin TJ, Chervoneva I, et al
    Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition.
    J Invest Dermatol. 2020 May 7. pii: S0022-202X(20)31406.
    PubMed     Abstract available

  10. ADAM C, Fusi L, Weiss N, Goller SG, et al
    Efficient suppression of NRAS-driven melanoma by co-inhibition of ERK1/2 and ERK5 MAPK pathways.
    J Invest Dermatol. 2020 May 3. pii: S0022-202X(20)31407.
    PubMed     Abstract available

    April 2020
  11. AVITAN-HERSH E, Feng Y, Vaisman AO, Ahmed YA, et al
    Regulation of eIF2alpha by RNF4 promotes melanoma tumorigenesis and therapy resistance.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31404.
    PubMed     Abstract available

  12. TIFFEN J, Gallagher S, Filipp F, Gunatilake D, et al
    EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma.
    J Invest Dermatol. 2020 Apr 29. pii: S0022-202X(20)31390.
    PubMed     Abstract available

  13. CHAVEZ A, Quesenberry CP Jr, Darbinian J, Asgari MM, et al
    Association of valproic acid use, a potent histone deacetylase inhibitor, and melanoma risk.
    J Invest Dermatol. 2020 Apr 27. pii: S0022-202X(20)31402.
    PubMed     Abstract available

  14. GUO Y, Zhang X, Zeng W, Zhang J, et al
    TRAF6 activates fibroblasts to cancer-associated fibroblasts (CAFs) through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31352.
    PubMed     Abstract available

  15. KUNG FF, Arias-Mejias SM, Quattrocchi E, Sominidi-Damodaran S, et al
    PD-1, PD-L1 and BIM as predictors of sentinel lymph node metastasis in primary cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31349.

  16. DIKA E, Riefolo M, Porcellini E, Broseghini E, et al
    Defining the prognostic role of microRNAs in cutaneous melanoma.
    J Invest Dermatol. 2020 Apr 7. pii: S0022-202X(20)31351.
    PubMed     Abstract available

  17. JENKINS RW, Fisher DE
    Treatment of Advanced Melanoma in 2020 and Beyond.
    J Invest Dermatol. 2020 Apr 5. pii: S0022-202X(20)31257.
    PubMed     Abstract available

  18. JOSHI SS, Hornyak TJ
    Cellular Phenotypic Plasticity of Cutaneous Melanoma: A Complex Puzzle.
    J Invest Dermatol. 2020;140:743-745.
    PubMed     Abstract available

    March 2020
  19. CHRISTODOULOU E, Nell RJ, Verdijk RM, Gruis NA, et al
    Loss of wild-type CDKN2A is an early event in the development of melanoma in FAMMM syndrome.
    J Invest Dermatol. 2020 Mar 28. pii: S0022-202X(20)31205.

    February 2020
  20. VESELY MD, Chen L
    Normalization Cancer Immunotherapy for Melanoma.
    J Invest Dermatol. 2020 Feb 21. pii: S0022-202X(20)30153.
    PubMed     Abstract available

  21. CHANG GA, Wiggins JM, Corless BC, Syeda MM, et al
    TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors.
    J Invest Dermatol. 2020 Feb 19. pii: S0022-202X(20)30159.
    PubMed     Abstract available

  22. PATEL S, Wilkinson CJ, Sviderskaya EV
    Loss of both CDKN2A and CDKN2B allows for centrosome overduplication in melanoma.
    J Invest Dermatol. 2020 Feb 14. pii: S0022-202X(20)30147.
    PubMed     Abstract available

    January 2020
  23. GUO D, Jain R, Hwang JS, Weninger W, et al
    RAB27A/Melanophilin blocker inhibits melanoma cell motility and invasion.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30036.

  24. BRAUN AD, Mengoni M, Bonifatius S, Tuting T, et al
    Activated Hgf-Met signaling cooperates with oncogenic Braf to drive primary cutaneous melanomas and angiotropic lung metastases in mice.
    J Invest Dermatol. 2020 Jan 20. pii: S0022-202X(20)30019.
    PubMed     Abstract available

  25. HONG CH, Ho JC, Lee CH
    Steroid receptor RNA activator (SRA), a long noncoding RNA, activates p38, facilitates epithelial mesenchymal transformation, and experimental melanoma metastasis.
    J Invest Dermatol. 2020 Jan 13. pii: S0022-202X(19)33503.
    PubMed     Abstract available

  26. SHELLMAN MH, Shellman YG
    Human against Machine? Machine Learning Identifies MicroRNA Ratios as Biomarkers for Melanoma.
    J Invest Dermatol. 2020;140:18-20.
    PubMed     Abstract available

    December 2019
  27. BARCELO C, Siso P, Maiques O, Garcia-Mulero S, et al
    T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF(V600E) melanoma: TTCCs are therapy target in BRAF(V600E) melanoma.
    J Invest Dermatol. 2019 Dec 23. pii: S0022-202X(19)33497.
    PubMed     Abstract available

    November 2019
  28. LIU X, Mi J, Qin H, Li Z, et al
    E2F1/IGF-1R loop contributes to BRAF inhibitor resistance in melanoma.
    J Invest Dermatol. 2019 Nov 6. pii: S0022-202X(19)33385.

    October 2019
  29. WENZINA J, Holzner S, Puujalka E, Cheng PF, et al
    Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)33299.
    PubMed     Abstract available

  30. ZENG H, Judson-Torres RL, Shain AH
    The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.
    J Invest Dermatol. 2019 Oct 14. pii: S0022-202X(19)32699.
    PubMed     Abstract available

    September 2019
  31. GIBBS DC, Orlow I, Vernali S, Powell HB, et al
    Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma.
    J Invest Dermatol. 2019 Sep 27. pii: S0022-202X(19)33239.

    August 2019
  32. ZHU G, Xu P, Guo S, Yi X, et al
    Metastatic melanoma cells rely on Sestrin2 to acquire anoikis resistance via detoxifying intracellular ROS.
    J Invest Dermatol. 2019 Aug 30. pii: S0022-202X(19)33208.
    PubMed     Abstract available

  33. TORRES R, Lang UE, Hejna M, Shelton SJ, et al
    MicroRNA ratios distinguish melanomas from nevi.
    J Invest Dermatol. 2019 Aug 22. pii: S0022-202X(19)31788.
    PubMed     Abstract available

  34. HARDIE CM, Elliott F, Chan M, Rogers Z, et al
    Environmental exposures such as smoking and low vitamin D are predictive of poor outcome in cutaneous melanoma rather than other deprivation measures.
    J Invest Dermatol. 2019 Aug 16. pii: S0022-202X(19)32703.
    PubMed     Abstract available

  35. SHAUGHNESSY M, Njauw CN, Artomov M, Tsao H, et al
    Classifying melanoma by TERT promoter mutational status.
    J Invest Dermatol. 2019 Aug 16. pii: S0022-202X(19)32704.
    PubMed     Abstract available

  36. HANOUNA G, Tang E, Perez J, Vandermeersch S, et al
    Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development.
    J Invest Dermatol. 2019 Aug 16. pii: S0022-202X(19)32702.
    PubMed     Abstract available

  37. DUFFY DL, Jagirdar K, Lee KJ, McWhirter SR, et al
    Genes determining nevus count and dermoscopic appearance in Australian melanoma cases and controls.
    J Invest Dermatol. 2019 Aug 14. pii: S0022-202X(19)32695.

  38. ZHOU S, Liang Y, Zhang X, Liao L, et al
    SHARPIN Promotes Melanoma Progression via Rap1 Signaling Pathway.
    J Invest Dermatol. 2019 Aug 8. pii: S0022-202X(19)32683.
    PubMed     Abstract available

    July 2019
  39. LEACHMAN SA, Hornyak TJ, Barsh G, Bastian BC, et al
    Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting.
    J Invest Dermatol. 2019 Jul 23. pii: S0022-202X(19)32550.

  40. SARGEN MR, Pfeiffer RM, Yang XR, Tucker MA, et al
    Variation in cutaneous patterns of melanomagenesis according to germline CDKN2A/CDK4 status in melanoma-prone families.
    J Invest Dermatol. 2019 Jul 18. pii: S0022-202X(19)32536.
    PubMed     Abstract available

  41. PEI S, Chen J, Lu J, Hu S, et al
    The Long Noncoding RNA UCA1 Negatively Regulates Melanogenesis in Melanocytes.
    J Invest Dermatol. 2019 Jul 2. pii: S0022-202X(19)31848.
    PubMed     Abstract available

  42. AIRA LE, Debes GF
    B Cells and Melanoma Pathogenesis.
    J Invest Dermatol. 2019;139:1422-1424.
    PubMed     Abstract available

    June 2019
  43. VOGEL FCE, Bordag N, Zugner E, Trajkovic-Arsic M, et al
    Targeting the H3K4 demethylase KDM5B reprograms the metabolome and phenotype of melanoma cells.
    J Invest Dermatol. 2019 Jun 20. pii: S0022-202X(19)31782.
    PubMed     Abstract available

  44. FANG S, Xu T, Xiong M, Zhou X, et al
    Role of immune response, inflammation and tumor immune response-related cytokines/chemokines in melanoma progression.
    J Invest Dermatol. 2019 Jun 6. pii: S0022-202X(19)31626.
    PubMed     Abstract available

    May 2019
  45. KOOPMANS I, Hendriks MAJM, van Ginkel RJ, Samplonius DF, et al
    Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade.
    J Invest Dermatol. 2019 May 22. pii: S0022-202X(19)31565.
    PubMed     Abstract available

    March 2019
  46. TAKABE P, Karna R, Rauhala L, Tammi M, et al
    Melanocyte hyaluronan coat fragmentation enhances the UVB-induced TLR-4 receptor signaling and expression of proinflammatory mediators IL-6, IL-8, CXCL-1 and CXCL-10 via NF-kappaB activation.
    J Invest Dermatol. 2019 Mar 29. pii: S0022-202X(19)31391.
    PubMed     Abstract available

  47. SANA G, Madigan JP, Gartner JJ, Fourrez M, et al
    Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased proliferative and invasive capacities.
    J Invest Dermatol. 2019 Mar 21. pii: S0022-202X(19)31330.
    PubMed     Abstract available

  48. KOBAYASHI T, Oishi K, Okamura A, Shintaro M, et al
    Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting Th1 cytokine production in tumor-infiltrating CD8(+) T cells.
    J Invest Dermatol. 2019 Mar 2. pii: S0022-202X(19)30186.
    PubMed     Abstract available

  49. MCKEAN M, Oba J, Ma J, Roth KG, et al
    Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
    J Invest Dermatol. 2019;139:728-731.

    February 2019
  50. DAVIDSON G, Coassolo S, Kieny A, Ennen M, et al
    Dynamic evolution of clonal composition and neoantigen landscape in recurrent metastatic melanoma with a rare combination of driver mutations.
    J Invest Dermatol. 2019 Feb 15. pii: S0022-202X(19)30108.
    PubMed     Abstract available

    January 2019
  51. ZHANG X, Peng Y, Li C, Li Q, et al
    Genomic heterogeneity and branched evolution of early-stage primary acral melanoma revealed by multi-regional microdissection sequencing.
    J Invest Dermatol. 2019 Jan 30. pii: S0022-202X(19)30045.
    PubMed     Abstract available

  52. NIKBAKHT N, Tiago M, Erkes DA, Chervoneva I, et al
    BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade.
    J Invest Dermatol. 2019 Jan 28. pii: S0022-202X(19)30026.

  53. INOZUME T, Yaguchi T, Ariyasu R, Togashi Y, et al
    Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy.
    J Invest Dermatol. 2019 Jan 23. pii: S0022-202X(19)30023.
    PubMed     Abstract available

  54. SHIN SY, Choi JH, Jung E, Gil HN, et al
    The EGR1-STAT3 Transcription Factor Axis Regulates alpha-MSH-induced Tyrosinase Gene Transcription in Melanocytes.
    J Invest Dermatol. 2019 Jan 12. pii: S0022-202X(19)30010.

  55. AVIGAD LARON E, Aamar E, Enshell-Seijffers D
    The Serine Protease Activity of Corin Is Required for Normal Pigment Type Switching.
    J Invest Dermatol. 2019;139:257-259.

    December 2018
  56. OLSEN CM, Green AC, Pandeya N, Whiteman DC, et al
    Trends in melanoma incidence rates in eight susceptible populations to 2015.
    J Invest Dermatol. 2018 Dec 19. pii: S0022-202X(18)30008.

  57. MILES JA, Orlow I, Kanetsky PA, Luo L, et al
    Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based GEM Study.
    J Invest Dermatol. 2018 Dec 17. pii: S0022-202X(18)32938.

  58. MURER P, Kiefer JD, Pluss L, Matasci M, et al
    Targeted delivery of TNF potentiates the antibody-dependent cell-mediated cytotoxicity of an anti-melanoma immunoglobulin.
    J Invest Dermatol. 2018 Dec 10. pii: S0022-202X(18)32928.
    PubMed     Abstract available

  59. CONWAY K, Edmiston SN, Parker JS, Kuan PF, et al
    Identification of a robust methylation classifier for cutaneous melanoma diagnosis.
    J Invest Dermatol. 2018 Dec 6. pii: S0022-202X(18)32916.
    PubMed     Abstract available

    November 2018
  60. FERRIS L, Moy R, Gerami P, Sligh JE, et al
    Non-Invasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma.
    J Invest Dermatol. 2018 Nov 27. pii: S0022-202X(18)32894.
    PubMed     Abstract available

  61. ATKINSON A, Renziehausen A, Wang H, Lo Nigro C, et al
    The collagen prolyl hydroxylases are bifunctional growth regulators in melanoma.
    J Invest Dermatol. 2018 Nov 16. pii: S0022-202X(18)32822.
    PubMed     Abstract available

  62. KIMLIN MG, Youlden DR, Brodie AM, DiSipio T, et al
    Risk of second primary cancer in survivors of in situ melanoma.
    J Invest Dermatol. 2018 Nov 10. pii: S0022-202X(18)32804.
    PubMed     Abstract available

    October 2018
  63. AMSCHLER K, Beyazpinar I, Erpenbeck L, Kruss S, et al
    Morphological Plasticity of Human Melanoma Cells is Determined by Nanoscopic Patterns of E- and N-Cadherin Interactions.
    J Invest Dermatol. 2018 Oct 27. pii: S0022-202X(18)32710.
    PubMed     Abstract available

  64. PETRIE T, Samatham R, Witkowski AM, Esteva A, et al
    Melanoma Early Detection: Big Data, Bigger Picture.
    J Invest Dermatol. 2018 Oct 25. pii: S0022-202X(18)32354.
    PubMed     Abstract available

  65. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Association between phenotypic characteristics and melanoma in a large prospective cohort study.
    J Invest Dermatol. 2018 Oct 24. pii: S0022-202X(18)32692.
    PubMed     Abstract available

    August 2018
  66. GILES KM, Rosenbaum BE, Berger M, Izsak A, et al
    Revisiting the clinical and biologic relevance of partial PTEN loss in melanoma.
    J Invest Dermatol. 2018 Aug 24. pii: S0022-202X(18)32503.
    PubMed     Abstract available

  67. PAMPENA R, Pellacani G, Longo C
    Nevus-Associated Melanoma: Patient Phenotype and Potential Biological Implications.
    J Invest Dermatol. 2018;138:1696-1698.
    PubMed     Abstract available

  68. SAHOO A, Sahoo SK, Joshi P, Lee B, et al
    MicroRNA-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma.
    J Invest Dermatol. 2018 Aug 1. pii: S0022-202X(18)32458.
    PubMed     Abstract available

    July 2018
  69. RAMSPOTT JP, Bekkat F, Bod L, Favier M, et al
    Emerging role of IL4-induced gene 1 as a prognostic biomarker affecting the local T cell response in human cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 23. pii: S0022-202X(18)32301.
    PubMed     Abstract available

  70. NOSRATI A, Yu WY, McGuire J, Griffin A, et al
    Outcomes and risk factors in patients with multiple primary melanomas.
    J Invest Dermatol. 2018 Jul 19. pii: S0022-202X(18)32359.
    PubMed     Abstract available

  71. ZHANG K, Anumanthan G, Scheaffer S, Cornelius LA, et al
    HMGB1/RAGE Mediates UVB-induced Secretory Inflammatory Response and Resistance to Apoptosis in Human Melanocytes.
    J Invest Dermatol. 2018 Jul 17. pii: S0022-202X(18)32348.
    PubMed     Abstract available

  72. FORSTHUBER A, Lipp K, Andersen L, Ebersberger S, et al
    CXCL5 as regulator of neutrophil function in cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 13. pii: S0022-202X(18)32353.
    PubMed     Abstract available

  73. TAKAISHI M, Sano S
    Transdifferentiation of melanoma cells by the reprogramming factors attenuates malignant nature in vitro and in vivo.
    J Invest Dermatol. 2018 Jul 7. pii: S0022-202X(18)32303.

    June 2018
  74. CUST AE, Drummond M, Kanetsky PA, Goldstein AM, et al
    Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies.
    J Invest Dermatol. 2018 Jun 8. pii: S0022-202X(18)32046.
    PubMed     Abstract available

    May 2018
  75. RAMANI V, Teshima T, Tamura K, Chung JS, et al
    Melanoma-derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-lymphocytes from the Pre-metastatic Niches.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31987.
    PubMed     Abstract available

  76. NAWAZ A, Wong TW
    Chitosan-carboxymethyl-5-fluorouracil-folate conjugate particles: Microwave modulated uptake by skin and melanoma cells.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31985.
    PubMed     Abstract available

  77. SEITZ-ALGHROUZ R, Hidalgo JV, Kayser C, Kreutz C, et al
    BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential (MELTUMPs).
    J Invest Dermatol. 2018 May 15. pii: S0022-202X(18)31973.

  78. THOMAS NE, Edmiston SN, Orlow I, Kanetsky PA, et al
    Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
    J Invest Dermatol. 2018 May 9. pii: S0022-202X(18)31962.
    PubMed     Abstract available

  79. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Physician skin checks before the diagnosis of melanoma correlate with tumor characteristics.
    J Invest Dermatol. 2018 May 4. pii: S0022-202X(18)31952.

    April 2018
  80. NORDLINGER A, Dror S, Elkahloun A, Del Rio J, et al
    Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
    J Invest Dermatol. 2018 Apr 18. pii: S0022-202X(18)31873.
    PubMed     Abstract available

    March 2018
  81. YANG Y, Guo W, Ma J, Xu P, et al
    Down-regulated TRPV1 expression contributes to melanoma growth via calcineurin-ATF3-p53 pathway.
    J Invest Dermatol. 2018 Mar 23. pii: S0022-202X(18)31748.
    PubMed     Abstract available

  82. PANDEYA N, Kvaskoff M, Olsen CM, Green AC, et al
    Factors related to nevus-associated cutaneous melanoma: a case-case study.
    J Invest Dermatol. 2018 Mar 7. pii: S0022-202X(18)30204.
    PubMed     Abstract available

  83. NEAL DE, Derwae AL, Etzkorn JR
    Cells to Surgery Quiz: March 2018.
    J Invest Dermatol. 2018;138:e33.

  84. GADDIS K, Chu EY
    SnapshotDx Quiz: March 2018.
    J Invest Dermatol. 2018;138:e31.

    February 2018
  85. SOLER-CARDONA A, Forsthuber A, Lipp K, Ebersberger S, et al
    CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis.
    J Invest Dermatol. 2018 Feb 20. pii: S0022-202X(18)30125.
    PubMed     Abstract available

  86. LIN J, Zhang D, Fan Y, Chao Y, et al
    Regulation of cancer stem cell self-renewal by HOXB9 antagonizes ER stress-induced melanoma cell apoptosis via the miR-765-FOXA2 axis.
    J Invest Dermatol. 2018 Feb 3. pii: S0022-202X(18)30105.
    PubMed     Abstract available

  87. TUCKER MA, Elder DE, Curry M, Fraser MC, et al
    Risks of melanoma and other cancers in melanoma-prone families over four decades.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30102.
    PubMed     Abstract available

  88. ELIADES P, Abraham BJ, Ji Z, Miller DM, et al
    High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30106.
    PubMed     Abstract available

  89. CARRERA C, Puig-Butille JA
    Clinical, Epidemiological, and Molecular Heterogeneity in Acral Melanoma.
    J Invest Dermatol. 2018;138:254-255.
    PubMed     Abstract available

  90. BEAULIEU D, Nijhawan RI
    Cells to Surgery Quiz: February 2018.
    J Invest Dermatol. 2018;138:e21.

    January 2018
  91. FAIAO-FLORES F, Smalley KSM
    Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.
    J Invest Dermatol. 2018;138:10-13.
    PubMed     Abstract available

    December 2017
  92. OGAWA H, Luxardi G, Kirane A, Kulkarni R, et al
    T cells dominate the local immune response induced by intralesional IL-2 in combination with imiquimod and retinoid for in-transit metastatic melanoma.
    J Invest Dermatol. 2017 Dec 29. pii: S0022-202X(17)33369.

  93. CONIC RZ, Arbesman J
    Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage.
    J Invest Dermatol. 2017 Dec 5. pii: S0022-202X(17)33236.

  94. KASUMOVA GG, Haynes AB, Boland GM
    Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application.
    J Invest Dermatol. 2017;137:2466-2468.
    PubMed     Abstract available

  95. CHHABRA G, Wojdyla L, Frakes M, Schrank Z, et al
    Mechanism of action of G-quadruplex forming oligonucleotide homologous to the telomere overhang in melanoma.
    J Invest Dermatol. 2017 Dec 1. pii: S0022-202X(17)33229.
    PubMed     Abstract available

    November 2017
  96. MOON KR, Choi YD, Kim JM, Jin S, et al
    Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    J Invest Dermatol. 2017 Nov 27. pii: S0022-202X(17)33225.
    PubMed     Abstract available

  97. LIU SM, Lin CH, Lu J, Lin IY, et al
    miR-596 modulates melanoma growth by regulating cell survival and death.
    J Invest Dermatol. 2017 Nov 25. pii: S0022-202X(17)33172.
    PubMed     Abstract available

  98. WANG YF, Liu F, Sherwin S, Farrelly M, et al
    Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells.
    J Invest Dermatol. 2017 Nov 22. pii: S0022-202X(17)33164.
    PubMed     Abstract available

  99. LOHCHAROENKAL W, Das Mahapatra K, Pasquali L, Crudden C, et al
    Genome-wide screen for microRNAs reveals a role for miR-203 in melanoma metastasis.
    J Invest Dermatol. 2017 Nov 2. pii: S0022-202X(17)33137.
    PubMed     Abstract available

    October 2017
  100. RUBEL F, Kern JS, Technau-Hafsi K, Uhrich S, et al
    Indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma correlates with Breslow thickness and is of significant prognostic value for progression-free survival.
    J Invest Dermatol. 2017 Oct 17. pii: S0022-202X(17)33059.
    PubMed     Abstract available

    September 2017
  101. HEPPT MV, Wang JX, Hristova DM, Wei Z, et al
    MSX1-induced neural crest-like reprogramming promotes melanoma progression.
    J Invest Dermatol. 2017 Sep 16. pii: S0022-202X(17)32807.
    PubMed     Abstract available

  102. HAO J, Xu H, Luo M, Yu W, et al
    The tumor-promoting role of TRIP4 in melanoma progression and its involvement in response to BRAF-targeted therapy.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32937.
    PubMed     Abstract available

  103. YU B, Alboslemy T, Safadi F, Kim MH, et al
    Glycoprotein non-melanoma clone B regulates the crosstalk between macrophages and mesenchymal stem cells towards wound repair.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32934.
    PubMed     Abstract available

  104. HAUGH AM, Zhang B, Quan VL, Garfield EM, et al
    Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
    J Invest Dermatol. 2017 Sep 1. pii: S0022-202X(17)32917.
    PubMed     Abstract available

    August 2017
  105. DONOVAN P, Dubey OA, Kallioinen S, Rogers KW, et al
    Paracrine Activin-A signaling promotes melanoma growth and metastasis through immune evasion.
    J Invest Dermatol. 2017 Aug 24. pii: S0022-202X(17)32820.
    PubMed     Abstract available

  106. DELYON J, Chevret S, Jouary T, Dalac S, et al
    STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.
    J Invest Dermatol. 2017 Aug 23. pii: S0022-202X(17)32802.
    PubMed     Abstract available

  107. THOMAS NE, Edmiston SN, Kanetsky PA, Busam KJ, et al
    Associations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32791.
    PubMed     Abstract available

  108. VON SCHUCKMANN LA, Smith D, Hughes MCB, Malt M, et al
    Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32797.
    PubMed     Abstract available

  109. TAYLOR NJ, Mitra N, Goldstein AM, Tucker MA, et al
    Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
    J Invest Dermatol. 2017 Aug 19. pii: S0022-202X(17)32759.
    PubMed     Abstract available

    July 2017
  110. DAI W, Xu X, Li S, Ma J, et al
    SOX4 promotes proliferative signals by regulating glycolysis through AKT activation in melanoma cells.
    J Invest Dermatol. 2017 Jul 28. pii: S0022-202X(17)32684.
    PubMed     Abstract available

  111. ISHIDA Y, Otsuka A, Tanaka H, Levesque MP, et al
    HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31863.

  112. CLARKE CA, McKinley M, Hurley S, Haile RW, et al
    Continued increase in melanoma incidence across all socioeconomic status groups in California, 1998-2012.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31867.
    PubMed     Abstract available

  113. GASSENMAIER M, Eigentler TK, Keim U, Goebeler M, et al
    Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31871.
    PubMed     Abstract available

    June 2017
  114. VAN TUYN J, Jaber-Hijazi F, MacKenzie D, Cole JJ, et al
    Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, A Candidate Melanoma Suppressor Function.
    J Invest Dermatol. 2017 Jun 21. pii: S0022-202X(17)31662.
    PubMed     Abstract available

  115. ASGARI MM, Chien AJ, Tsai AL, Fireman B, et al
    Association between lithium use and melanoma risk and mortality: A population-based study.
    J Invest Dermatol. 2017 Jun 16. pii: S0022-202X(17)31644.
    PubMed     Abstract available

  116. THEODOSAKIS N, Micevic G, Langdon CG, Ventura A, et al
    p90RSK blockade inhibits dual BRAF and MEK inhibitor-resistant melanoma by targeting protein synthesis.
    J Invest Dermatol. 2017 Jun 6. pii: S0022-202X(17)31603.
    PubMed     Abstract available

    May 2017
  117. BUSTOS MA, Ono S, Marzese DM, Oyama T, et al
    MiR-200a Regulates CDK4/6 Inhibitor Effect by targeting CDK6 in Metastatic Melanoma.
    J Invest Dermatol. 2017 May 16. pii: S0022-202X(17)31528.
    PubMed     Abstract available

  118. SHI Q, Liu H, Han P, Li C, et al
    Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.
    J Invest Dermatol. 2017 May 9. pii: S0022-202X(17)31489.
    PubMed     Abstract available

  119. LEITER U, Keim U, Eigentler T, Katalinic A, et al
    Incidence, Mortality and Trends of Non-Melanoma Skin Cancer in Germany.
    J Invest Dermatol. 2017 May 6. pii: S0022-202X(17)31482.
    PubMed     Abstract available

  120. BAUER J
    The Molecular Revolution in Cutaneous Biology: Era of Cytogenetics and Copy Number Analysis.
    J Invest Dermatol. 2017;137:e57-e59.
    PubMed     Abstract available

    April 2017
  121. FANG S, Wang Y, Dang Y, Gagel A, et al
    Association between body mass index, C-reactive protein levels, and melanoma patient outcomes.
    J Invest Dermatol. 2017 Apr 22. pii: S0022-202X(17)31423.

  122. KIM SH, Li M, Trousil S, Zhang Y, et al
    Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma.
    J Invest Dermatol. 2017 Apr 19. pii: S0022-202X(17)31420.
    PubMed     Abstract available

  123. SEO EY, Jin SP, Sohn KC, Park CH, et al
    UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes.
    J Invest Dermatol. 2017 Apr 6. pii: S0022-202X(17)31396.
    PubMed     Abstract available

  124. SFECCI A, Dupuy A, Dinulescu M, Droitcourt C, et al
    Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
    J Invest Dermatol. 2017;137:805-809.
    PubMed     Abstract available

    February 2017
  125. PUIG-BUTILLE JA, Vinyals A, Ferreres JR, Aguilera P, et al
    AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK/ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy.
    J Invest Dermatol. 2017 Feb 7. pii: S0022-202X(17)30115.
    PubMed     Abstract available

  126. ZHOU Y, Tripathi SV, Rosman I, Ma J, et al
    Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.
    J Invest Dermatol. 2017 Feb 2. pii: S0022-202X(17)30104.

    January 2017
  127. TROUSIL S, Chen S, Mu C, Shaw FM, et al
    Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
    J Invest Dermatol. 2017 Jan 28. pii: S0022-202X(17)30052.
    PubMed     Abstract available

  128. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.

    December 2016
  129. ROOS L, Sandling JK, Bell CG, Glass D, et al
    Higher Naevus Count Exhibits A Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.
    J Invest Dermatol. 2016 Dec 16. pii: S0022-202X(16)32787.
    PubMed     Abstract available

  130. KAWAKAMI A, Fisher DE
    Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    J Invest Dermatol. 2016;136:2342-2344.
    PubMed     Abstract available

    November 2016
  131. MELAMED RD, Aydin IT, Rajan GS, Phelps R, et al
    Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    J Invest Dermatol. 2016 Nov 24. pii: S0022-202X(16)32663.
    PubMed     Abstract available

  132. CHIANG NY, Peng YM, Juang HH, Chen TC, et al
    GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated Galpha12/13/RhoA signaling.
    J Invest Dermatol. 2016 Nov 3. pii: S0022-202X(16)32618.
    PubMed     Abstract available

    October 2016
  133. KOHLI JS, Tolomio E, Frigerio S, Maurichi A, et al
    Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.
    J Invest Dermatol. 2016 Oct 28. pii: S0022-202X(16)32610.

  134. ELIADES P, Tsao H
    New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi-Highlighting the Keratinocyte-Melanocyte Relationship.
    J Invest Dermatol. 2016;136:1933-5.
    PubMed     Abstract available

    September 2016
  135. VIARISIO D, Muller-Decker K, Hassel JC, Alvarez JC, et al
    The BRAF inhibitor vemurafenib enhances UV-induced skin carcinogenesis in beta HPV38 E6 and E7 transgenic mice.
    J Invest Dermatol. 2016 Sep 17. pii: S0022-202X(16)32449.

  136. LUCARINI V, Buccione C, Ziccheddu G, Peschiaroli F, et al
    Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to improve anti-tumor response against melanoma.
    J Invest Dermatol. 2016 Sep 10. pii: S0022-202X(16)32368.
    PubMed     Abstract available

    July 2016
  137. WEIDE B, Schafer T, Martens A, Kuzkina A, et al
    High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32125.
    PubMed     Abstract available

    May 2016
  138. POSCH C, Sanlorenzo M, Vujic I, Oses-Prieto JA, et al
    Phospho-proteomic analyses of NRAS(G12) and NRAS(Q61) mutant melanocytes reveal increased CK2alpha kinase levels in NRAS(Q61) mutant cells.
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31261.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.